Aromatase inhibitors for breast cancer

Susanne Briest, Nancy E. Davidson

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Endocrine therapy is a mainstay for the many women who develop in situ or invasive steroid receptor-positive breast cancer. The use of tamoxifen has reduced mortality in such women. Recently estrogen deprivation strategies have come under scrutiny. Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed.

Original languageEnglish (US)
Pages (from-to)215-228
Number of pages14
JournalReviews in Endocrine and Metabolic Disorders
Issue number3
StatePublished - Sep 2007
Externally publishedYes


  • Aromatase inhibitor
  • Breast cancer
  • Endocrine treatment
  • Estrogen receptor
  • Hormonal therapy
  • Postmenopausal

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Aromatase inhibitors for breast cancer'. Together they form a unique fingerprint.

Cite this